Nocion Therapeutics, Inc.

Nocion Therapeutics is a clinical-stage biopharmaceutical company in the Boston area developing a new class of small-molecule 'charged' sodium channel blockers - nocions - that selectively, locally, and durably silence overactive sensory neurons (nociceptors) without numbing everything else. Its lead candidate, taplucainium, is an inhaled powder aimed at refractory and unexplained chronic cough, with broader potential across itch, pain, and neurogenic inflammation. The science was born in the Harvard Medical School and Boston Children's Hospital labs of Bruce Bean and Clifford Woolf.